ArticleFrontiers in pharmacology2025

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system.

Shiyi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.